VEGFA and myocardial infarction: Anti-VEGF treatment as anti-angiogenic therapy in cancer is associated with an increased risk of adverse effects including MI, hypertension, proteinuria, arterial thromboembolism, cardiac ischemia and dysfunction affecting 1–15% of treated patients [13,14].